Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures Abstract #1173

Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR
Aim(s): To verify the effects of Sunitinib on human Pheochromocytoma and Paraganglioma primary cultures
Materials and methods: 5 primary cultures (4 Pheochromocytoma and 1 Paraganglioma) were obtained from patients, followed in our centre, whose data about age, genetic alteration, histological features, and clinical events had been collected. Cell viability and apoptosis were measured by ATPlite and Caspase 3/7 assay.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Teresa Gagliano

To read results and conclusion, please login ...

Further abstracts you may be interested in

#99 Gene mutations and Hypoxia Inducible Factor (HIF-1) expression as prognostic-predictive factors in pheochromocytomas/paragangliomas (P/P)
Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta
#566 A Case Report of a Patient with Metastatic Cervical Paraganglioma Responding to the Tyrosine Kinase Inhibitor Sunitinib
Introduction: Paragangliomas are rare neuroendocrine neoplasms that arise from neural crest cells, and are associated with increased expression of angiogenic growth factors. There have been isolated case reports describing potential efficacy with Sunitinib, a tyrosine kinase inhibitor.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olga Oikonomidou
#1729 Outstanding Response to Sunitinib in a Patient with Unresectable Retroperitoneal Paraganglioma
Introduction: Pheochromocitomas and Paragangliomas (PCs/PGLs) are rare neuroendocrine tumors arising from the adrenal medulla and extra-adrenal ganglia. Around 30-40% of these neoplasms are genetically determined. PCs/PGLs arising from the sympathetic chain can synthesize bioactive amines leading to typical syndromes, in contrast to parasympathetic PGLs that are mainly non-secretory.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu
#246 SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathethic Paragangliomas, but Not Through Hypoxia Signalling
Introduction: To date there is no reliable histopathological marker of malignancy for pheochromocytomas/sympathetic paragangliomas (PCC/PGL). It is well-known that PCC/PGL in the hereditary context of an SDHB germline mutation very often metastasize. The immunohistochemical loss of SDHB expression was recently shown to be a surrogate marker for the presence of an SDH germline mutation in PCC/PGL. SDHB loss is supposed to be tumorigenic via activation of hypoxia signals.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Anja M Schmitt
#590 Imaging of Metastatic-Recurrent Paragangliomas and Pheochromocytomas with Ga-68 DOTATATE PET/CT
Introduction: Approximately 73% of Pheochromocytomas(Pheo) and 93% of paragangliomas(PGL) express somatostatin receptors and Ga-68 DOTATATE PET/CT may have a role in metastatic PHEO/PGLs for determination of extent of disease.
Conference:
Category: Clinical
Presenting Author: Dr. emre demirci
Authors: demirci E, ocak M, kabasakal L, yeyin N, ...